CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is a dual-peptide research combination investigated for synergistic stimulation of endogenous growth hormone (GH) release.

• CJC-1295 (a GHRH analogue) acts at the growth hormone–releasing hormone receptor to promote physiologic GH secretion.

• Ipamorelin (a selective ghrelin receptor agonist) stimulates GH release via activation of the GHS-R1a receptor.
  

In experimental models, the combination has been studied for its effects on pulsatile GH secretion, increased insulin-like growth factor 1 (IGF-1) levels, and broader endocrine pathway modulation. The dual-receptor approach is of interest in research exploring synergistic neuroendocrine signaling.